≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback

Malignant neoplasm of thymus, including Hilmo

Endpoint Browser PheWeb

C3_THYMUS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — C37&
  • Hospital discharge: ICD-9 — 1640
  • Cause of death: ICD-10 — C37&
  • Cause of death: ICD-9 — 1640
  • Cancer registry: Topography ICD-O-3 — C37
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

3 out of 7 registries used, show all original rules.

153

4. Check minimum number of events

None

153

5. Include endpoints

None

153

6. Filter based on genotype QC (FinnGen only)

143

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 143 68 75
Unadjusted period prevalence (%) 0.03 0.02 0.03
Median age at first event (years) 63.18 63.82 62.60

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
153
Matched controls
1530
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C37
ICD-10 Finland
Malignant neoplasm of thymus
+∞
92.3
79
*
D38.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Mediastinum
+∞
79.2
69
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
21.3
73.4
67
54
D38.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Thymus
+∞
64.2
57
*
GEC24
NOMESCO Finland
Thoracoscopic thymectomy
748.8
55.2
51
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
20.1
52.4
45
31
130
Kela drug reimbursment
Malignant tumour
+∞
49.7
45
*
D15.0
ICD-10 Finland
Benign neoplasm: Thymus
+∞
46.2
42
*
A03FA01
ATC
metoclopramide; systemic, rectal
9.8
40.3
61
97
H02AB02
ATC
dexamethasone; systemic
114.5
40.2
42
5
GD1AD
NOMESCO Finland
Thorax CT examination
15.5
39.2
38
32
GEC23
NOMESCO Finland
Transsternal thymectomy
+∞
38.1
35
*
JN4BD
NOMESCO Finland
Extensive body CT
14.4
35.8
36
32
8580/3-C37.9
ICD-O-3
Thymoma, NOS, of thymus
+∞
34.7
32
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
31.3
29
*
8582/3-C37.9
ICD-O-3
Thymoma, type AB of thymus
+∞
29.1
27
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
7.2
29.0
114
443
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
6.4
25.9
58
134
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
25.7
24
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
25.7
24
*
XX3DW
NOMESCO Finland
Time consuming IT work
11.2
24.3
28
30
WX408
NOMESCO Finland
General anesthesy, balanced
5.5
24.0
71
209
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
23.5
22
*
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
254.9
22.2
22
*
JN4AD
NOMESCO Finland
Body CT examination
9.6
21.6
28
35
WF002
NOMESCO Finland
Radical radiotherapy
89.3
21.3
23
*
A04AA02
ATC
granisetron; systemic, transdermal
241.5
21.1
21
*
B01AB05
ATC
enoxaparin; parenteral
4.9
21.1
76
258
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
20.2
19
*
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
120.8
20.1
21
*
ZXC96
NOMESCO Finland
Robot assisted procedure
215.3
19.0
19
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
215.3
19.0
19
*
A04AA01
ATC
ondansetron; systemic, rectal
25.8
18.9
26
12
N02AA05
ATC
oxycodone; systemic
5.5
18.3
43
101
WX402
NOMESCO Finland
General anaesthesia
4.9
18.1
52
145
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
18.1
17
*
L03AA13
ATC
pegfilgrastim; parenteral
202.5
17.9
18
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
7.6
17.3
27
42
WX302
NOMESCO Finland
Thoracal epidural anesthesy
31.8
17.0
22
8
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
101.3
16.9
18
*
GEB30
NOMESCO Finland
Mediastinotomy and excision of lesion
+∞
15.9
15
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
15.9
15
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
6.0
15.8
32
65
WZC00
NOMESCO Finland
Treatment plan or consultation
4.0
15.7
68
255
Z51.5
ICD-10 Finland
Palliative care
17.5
15.5
24
16
J18.9
ICD-10 Finland
Pneumonia, unspecified
4.1
15.2
58
198
N07AA02
ATC
pyridostigmine; systemic
63.2
15.1
17
*
G70.0
ICD-10 Finland
Myasthenia gravis
88.9
14.9
16
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
14.8
14
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
14.8
14
*
TPH07
NOMESCO Finland
Cathetrisation of artery
5.5
14.5
32
70
WZC30
NOMESCO Finland
Teaching
5.0
14.5
37
92
ZX120
NOMESCO Finland
Intravenous
6.8
14.5
25
43
R4110
NOMESCO Finland
Physiotherapy
3.7
13.1
61
235
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
12.7
12
*
L01BC06
ATC
capecitabine; oral
+∞
12.7
12
*
108
Kela drug reimbursment
Myasthenia gravis
70.5
11.8
13
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.2
11.7
27
61
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
11.6
11
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
11.6
11
*
C38.1
ICD-10 Finland
Malignant neoplasm: Anterior mediastinum
+∞
11.6
11
*
L03AA02
ATC
filgrastim; parenteral
129.3
11.6
12
*
ZXE20
NOMESCO Finland
More than three and less than five hours
4.2
11.1
34
97
WX892
NOMESCO Finland
Monitored bed care
5.5
10.9
23
48
L01CB01
ATC
etoposide; systemic
+∞
10.5
10
*
116
Kela drug reimbursment
Prostate cancer
+∞
10.5
10
*
8581/3-C37.9
ICD-O-3
Thymoma, type A of thymus
+∞
10.5
10
*
A04AD12
ATC
aprepitant; systemic
+∞
10.5
10
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.4
10.3
48
182
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
16.1
10.3
16
11
B01AB04
ATC
dalteparin; parenteral
9.7
9.6
19
22
GD5AD
NOMESCO Finland
Thorax and upper abdomen combined CT examination of
32.3
9.6
12
*
D15.2
ICD-10 Finland
Benign neoplasm: Mediastinum
+∞
9.5
9
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
9.5
9
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.9
9.1
63
297
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
25.8
9.1
12
5
L02AE02
ATC
leuprorelin; implant, parenteral
53.1
8.8
10
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
21.5
8.6
12
6
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
5.1
8.6
19
41
JN6AD
NOMESCO Finland
CT of torso and neck
29.4
8.6
11
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
95.1
8.5
9
*
GAA31
NOMESCO Finland
Thoracoscopy
+∞
8.4
8
*
8583/3-C37.9
ICD-O-3
Thymoma, type B1 of thymus
+∞
8.4
8
*
8585/3-C37.9
ICD-O-3
Thymoma, type B3 of thymus
+∞
8.4
8
*
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
+∞
8.4
8
*
R50.9
ICD-10 Finland
Fever, unspecified
3.5
7.9
31
104
N03AX16
ATC
[U] pregabalin
2.9
7.9
48
209
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
4.5
7.8
20
49
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
10.9
7.7
14
14
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
7.1
7.7
18
28
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
6.4
7.5
19
33
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
7.3
7
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
7.3
7
*
8070/3-C37.9
ICD-O-3
Squamous cell carcinoma, NOS, of thymus
+∞
7.3
7
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
7.3
7
*
D48.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other specified sites
+∞
7.3
7
*
N02AX02
ATC
tramadol; systemic, rectal
2.5
7.3
81
473
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.0
6.8
16
25
J01MA12
ATC
levofloxacin; systemic
2.9
6.8
37
151
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
10.7
6.7
12
12
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
72.8
6.5
7
*
A02BC02
ATC
pantoprazole; systemic
2.6
6.5
113
795
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.6
6.5
23
72
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
5.5
6.4
18
36
WW500
NOMESCO Finland
Blood transfusion
11.7
6.4
11
10
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
6.3
6
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
6.3
6
*
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
+∞
6.3
6
*
115
Kela drug reimbursment
Breast cancer
+∞
6.3
6
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
6.3
6
*
C38.3
ICD-10 Finland
Malignant neoplasm: Mediastinum, part unspecified
+∞
6.3
6
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
6.3
6
*
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
+∞
6.3
6
*
GE1CT
NOMESCO Finland
Mediastinal biopsy with CT guidance
+∞
6.3
6
*

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
61
30
33.15
84.65
1.8
1.2
—
—
—
0
0
96
309
6.66
30.59
3.0
1.9
—
—
—
0
0
38
58
8.39
25.15
3.1
1.7
2.11
2.26
ug/l
0.23
27
45
130
636
7.95
23.67
18.0
6.1
3.92
4.16
e9/l
0.77
115
558
113
491
5.98
23.61
3.4
2.2
—
—
—
0
0
78
253
5.25
23.32
14.2
4.3
—
—
—
0
0
34
50
8.46
23.13
10.8
6.5
25.90
25.25
mmol/l
0.38
34
50
120
556
6.37
22.99
11.4
12.7
1.11
1.30
inr
2.05
25
153
42
84
6.51
21.44
1.3
1.0
—
—
—
0
0
50
121
5.65
20.80
13.3
5.3
104.26
104.33
mmol/l
0.03
50
121
113
525
5.41
20.78
9.2
5.5
—
—
—
0
0
34
57
7.38
20.50
9.5
8.9
—
—
—
0
0
75
258
4.74
20.32
6.8
2.9
90.08
88.75
%
0.17
75
250
117
568
5.50
20.10
8.6
5.0
0.60
0.56
e9/l
1.06
100
495
117
568
5.50
20.10
8.6
5.0
0.04
0.04
e9/l
0.62
100
498
119
586
5.64
20.06
9.9
5.1
0.14
0.19
e9/l
4.85
103
516
112
527
5.20
19.98
12.3
5.4
1.21
1.21
mmol/l
0.35
101
460
118
579
5.54
19.93
8.7
5.1
1.68
1.84
e9/l
0.44
101
519
33
59
6.86
18.66
17.7
7.9
0.62
0.73
%
0.89
33
59
33
61
6.62
18.04
17.5
7.8
1.16
1.58
%
1.12
33
61
87
360
4.28
17.88
2.6
1.6
—
—
—
0
0
47
123
5.07
17.62
13.3
7.3
5.46
5.29
kpa
0.53
47
117
47
123
5.07
17.62
13.3
7.3
13.51
11.41
kpa
1.28
47
118
73
275
4.16
16.93
5.3
3.4
—
—
—
0
0
37
82
5.63
16.70
16.7
6.6
—
—
—
0
0
30
64
5.59
13.99
1.1
1.5
—
—
—
0
0
97
492
3.65
13.65
14.7
6.9
0.00
0.00
e9/l
0.49
79
392
68
282
3.54
13.05
3.5
2.7
0.19
0.43
e6/l
1.13
56
199
17
7
27.07
12.77
2.6
1.6
24.20
13.32
ug/l
—
17
7
72
313
3.46
12.76
6.4
2.8
7.40
7.40
ph
—
10
47
16
6
29.50
12.32
4.9
1.5
4.74
4.62
nmol/l
—
16
6
49
170
3.77
12.24
3.4
2.7
4.77
3.23
e6/l
0.26
33
82
71
320
3.27
11.65
3.5
2.7
71.77
33.41
e6/l
0.48
59
237
73
335
3.26
11.61
9.3
2.0
2.36
2.35
mmol/l
0.21
68
287
65
281
3.28
11.39
3.6
2.5
—
—
—
0
0
46
161
3.66
11.25
1.7
1.7
—
—
—
0
0
77
376
3.11
10.84
4.1
3.3
85.53
55.25
e6/l
0.22
61
255
64
287
3.11
10.37
1.4
1.3
—
—
—
0
0
29
77
4.41
10.34
2.3
1.9
65.31
66.98
g/l
0.65
29
69
38
125
3.71
10.10
2.1
2.4
22.82
26.44
%
0.71
38
110
39
132
3.62
9.93
1.2
1.4
—
—
—
0
0
41
152
3.32
9.00
2.1
2.0
—
—
—
0
0
50
210
3.05
8.89
2.1
2.1
5.17
4.24
e6/l
0.18
45
187
54
240
2.93
8.65
2.0
1.7
1.18
1.08
mg/l
0.14
44
184
33
113
3.45
8.16
1.2
1.5
—
—
—
0
0
11
5
23.52
8.14
2.8
2.0
31.95
46.84
%
—
11
5
46
196
2.93
7.87
2.0
2.5
565.03
557.57
mosm/kgh2o
0.07
40
163
25
73
3.90
7.78
1.6
1.3
0.87
1.27
g/l
1.69
19
68
53
249
2.73
7.51
1.8
1.9
3.15
2.89
mg/l
0.30
47
211
7
0
+∞
7.34
2.1
0.0
20.29
—
u/ml
—
7
0
145
1219
4.62
6.16
30.8
10.9
32.40
22.52
mg/l
3.00
140
909
17
35
5.33
5.95
1.8
2.0
1.43
1.58
ug/l
0.04
17
30
24
88
3.05
5.23
1.4
1.5
—
—
—
0
0
20
67
3.28
5.04
1.3
1.2
31.31
321.41
u/ml
1.97
14
61
108
790
2.25
4.96
4.1
3.8
—
—
—
0
0
47
252
2.25
4.74
3.2
3.6
43.62
225.37
ng/l
2.01
39
202
31
139
2.54
4.64
1.2
1.4
—
—
—
0
0
131
1058
2.66
4.52
36.2
12.7
15.02
14.82
%
0.18
131
1042
19
73
2.83
3.81
2.8
1.3
—
—
—
0
0
26
120
2.41
3.64
2.3
1.9
7.42
9.99
umol/l
0.30
26
105
21
88
2.61
3.58
5.6
2.4
55.65
63.81
e9/l
0.49
15
66
19
78
2.64
3.37
6.7
5.8
—
—
—
0
0
79
563
1.83
3.36
4.6
4.4
0.00
0.00
estimate
-0.00
15
87
18
74
2.62
3.18
6.0
3.9
68.28
88.76
ng/l
1.08
18
68
79
571
1.79
3.14
3.3
3.2
0.00
0.00
estimate
-0.00
15
85
147
1342
3.43
3.08
35.1
12.4
78.80
77.47
umol/l
0.19
147
1342
68
474
1.78
3.03
4.2
3.3
51.07
43.10
ng/l
0.12
52
318
77
558
1.76
2.99
3.3
3.2
0.00
0.01
estimate
0.49
15
94
111
896
1.87
2.98
4.2
3.7
—
—
—
0
0
6
9
6.88
2.89
2.8
5.3
—
—
—
0
0
56
375
1.78
2.82
3.4
2.3
62.64
69.70
u/l
0.22
56
345
30
164
2.03
2.79
1.4
1.3
780.00
578.89
titre
—
8
36
36
211
1.92
2.75
1.2
1.3
912.44
28.15
iu/ml
0.46
11
65
12
42
3.01
2.61
3.9
2.2
185.17
444.07
ug/l
0.84
12
37
42
266
1.80
2.51
3.8
3.2
—
—
—
0
0
7
16
4.53
2.50
1.3
1.3
—
—
—
0
0
7
16
4.53
2.50
1.4
1.1
—
—
—
0
0
8
21
3.96
2.50
1.8
3.2
—
—
—
0
0
37
230
1.80
2.34
1.8
1.3
2.22
2.57
g/l
0.60
29
142
11
40
2.88
2.33
3.9
1.1
34.97
37.88
g/l
0.66
11
35
7
18
4.02
2.28
1.3
2.2
—
—
—
0
0
9
30
3.12
2.18
3.1
2.9
—
—
—
0
0
45
302
1.69
2.18
2.5
3.0
—
—
—
0
0
7
19
3.81
2.18
1.3
1.0
—
—
—
0
0
7
20
3.62
2.08
1.0
1.3
—
—
—
0
0
118
1307
0.58
2.03
4.2
5.1
2.72
2.78
mmol/l
0.34
112
1218
143
1310
2.40
1.99
22.8
10.3
—
—
—
0
0
23
132
1.87
1.86
1.4
1.3
—
—
—
0
0
6
17
3.63
1.85
2.0
2.5
4.95
5.13
kpa
—
6
17
6
17
3.63
1.85
2.0
2.5
8.75
8.13
kpa
—
6
17
6
18
3.42
1.76
1.3
3.7
61.33
60.83
%
—
6
18
6
18
3.42
1.76
1.0
1.3
189.33
51.81
pmol/l
—
6
18
6
18
3.42
1.76
1.3
2.7
4.12
5.20
e9/l
—
6
18
7
24
3.01
1.74
1.6
1.3
—
—
—
0
0
5
13
3.94
1.73
1.2
1.9
—
—
—
0
0
5
13
3.94
1.73
3.0
1.3
—
—
—
0
0
5
14
3.65
1.63
1.2
2.1
—
—
—
0
0
7
26
2.77
1.60
1.3
1.1
—
—
—
0
0
6
20
3.08
1.59
1.0
1.0
—
—
—
0
0
17
93
1.93
1.59
2.6
3.1
206.71
135.89
ng/l
0.67
17
85
10
44
2.36
1.59
1.1
1.2
—
—
—
0
0
11
51
2.25
1.54
5.5
2.1
—
—
—
0
0
42
301
1.54
1.52
2.0
2.9
—
—
—
0
0
23
141
1.74
1.52
2.4
1.9
130.95
86.84
ug/g
0.42
23
114
117
1280
0.63
1.50
3.8
4.5
4.67
4.67
mmol/l
0.01
110
1193
16
88
1.91
1.48
1.1
1.2
—
—
—
0
0
20
119
1.78
1.46
1.6
1.7
—
—
—
0
0
5
16
3.19
1.45
1.4
1.3
—
—
—
0
0
6
22
2.80
1.45
1.3
1.2
—
—
—
0
0
45
336
1.48
1.34
4.1
3.6
—
—
—
0
0
117
1273
0.66
1.32
3.7
4.5
1.45
1.45
mmol/l
0.00
111
1183
9
44
2.11
1.29
2.3
1.8
—
—
—
0
0
14
78
1.87
1.26
1.9
3.3
—
—
—
0
0
147
1402
2.24
1.23
43.4
16.2
130.10
138.71
g/l
8.05
147
1376
147
1401
2.26
1.23
44.7
16.0
38.67
41.09
%
4.37
140
1302
147
1401
2.26
1.23
42.9
16.0
30.22
30.40
pg
0.59
147
1376
147
1401
2.26
1.23
43.0
16.1
91.38
91.02
fl
0.42
147
1376
8
38
2.16
1.20
17.6
4.0
—
—
—
0
0
6
26
2.36
1.20
1.0
3.2
—
—
—
0
0
7
139
0.48
1.16
1.4
1.4
—
—
—
0
0
5
20
2.55
1.16
1.0
1.2
—
—
—
0
0
59
477
1.39
1.12
1.7
1.8
90.12
93.85
pmol/l
0.31
38
222
5
21
2.43
1.10
1.0
1.0
—
—
—
0
0
5
21
2.43
1.10
1.0
1.8
72.00
65.36
%
—
5
21
7
33
2.17
1.07
14.1
4.3
3.81
3.91
mmol/l
—
7
33
7
33
2.17
1.07
1.9
1.8
—
—
—
0
0
12
68
1.83
1.04
4.3
2.8
1.23
1.21
mmol/l
0.63
12
59
23
159
1.53
0.98
1.4
1.2
—
—
—
0
0
38
293
1.40
0.94
3.6
3.4
0.00
0.01
estimate
0.49
12
84
28
206
1.44
0.90
1.2
1.3
2.35
8.80
u/ml
—
8
78
16
105
1.58
0.85
5.1
1.7
324.25
368.52
nmol/l
0.55
16
94
8
46
1.78
0.84
5.8
2.2
0.61
0.59
%
—
8
46
8
48
1.70
0.80
5.8
2.1
1.27
1.21
%
—
8
48
115
1227
0.75
0.77
3.5
4.0
1.33
1.32
mmol/l
0.04
109
1131
99
909
1.25
0.63
3.6
3.6
15.13
14.73
pmol/l
0.74
92
824
122
1149
1.30
0.62
4.3
4.2
1.91
1.90
mu/l
0.02
116
1055
39
465
0.78
0.62
2.6
2.9
—
—
—
0
0
11
73
1.55
0.58
2.0
1.5
—
—
—
0
0
131
1251
1.33
0.55
4.2
4.4
5.84
5.99
mmol/l
0.86
122
1151
14
100
1.44
0.54
7.1
3.6
—
—
—
0
0
9
64
1.43
0.52
1.1
1.3
—
—
—
0
0
8
61
1.33
0.40
2.5
3.5
4.13
4.64
pmol/l
—
8
54
7
52
1.36
0.31
3.0
2.8
—
—
—
0
0
14
111
1.29
0.31
1.3
1.3
—
—
—
0
0
12
93
1.32
0.31
6.7
2.8
—
—
—
0
0
10
76
1.34
0.29
2.9
2.2
—
—
—
0
0
30
264
1.17
0.27
4.2
3.5
1.02
1.02
kg/l
—
6
35
5
73
0.67
0.26
1.0
1.1
—
—
—
0
0
7
91
0.76
0.23
1.3
1.2
—
—
—
0
0
10
79
1.28
0.23
1.9
1.5
—
54.64
—
0
9
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
7.7
—
0.65
—
0
10
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
285.50
—
0
10
37
404
0.89
0.21
4.0
3.7
12.47
8.88
mg/mmol
0.22
24
259
0
14
0.00
0.20
0.0
1.3
—
180.87
—
0
14
0
14
0.00
0.20
0.0
1.1
—
1.55
—
0
14
36
382
0.92
0.11
3.4
3.2
67.51
230.64
mg/l
0.48
27
248
5
45
1.11
0.10
1.4
1.1
—
—
—
0
0
7
65
1.08
0.08
2.1
2.4
—
—
—
0
0
27
259
1.05
0.04
3.5
2.4
0.90
0.71
ug/l
0.53
21
156
10
92
1.09
0.03
1.4
1.3
—
—
—
0
0
12
128
0.93
0.02
1.6
1.6
—
—
—
0
0
25
252
0.99
0.00
1.1
1.3
1.27
0.99
u/ml
—
9
71
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
153.21
—
0
8
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
79.42
—
0
6
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
8.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
9.57
—
0
7
0
5
0.00
-0.00
0.0
10.2
—
26.20
—
0
5
0
5
0.00
-0.00
0.0
8.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.5
—
2225.00
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
1.47
—
0
6
0
7
0.00
-0.00
0.0
5.9
—
0.29
—
0
7
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: C3_THYMUS_WIDE – Malignant neoplasm of thymus, including Hilmo

GWS hits: 1

This endpoint is excluded (different definition than used in FinnGen).